MEDP Earnings

MEDP reported its earnings on 2026-04-22, showcasing a revenue of 706.60M against an estimate of 694.24M, resulting in a 1.78% surprise. The EPS was 4.28, surpassing the expected 3.74 by 14.44%. The stock experienced a -22.63% price change on the earnings day and a -19.43% change over the next five days, reflecting market reactions to the results.

Following MEDP's earnings announcement on 2026-04-22, the stock price moved by -22.63% on the day of the release. Over the subsequent five days, it saw a -19.43% change. Historically, MEDP's stock price tends to shift by an average of -0.15% in the 10 days leading up to earnings and 5.93% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate MEDP's annual revenue to reach 690.52M, while the EPS is projected at 4.09. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between MEDP's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, MEDP's stock price typically moves by -0.15% in the 10 days before its earnings and 5.93% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 4.09 and revenue of 690.52M.

The earnings call presented a mixed picture: strong revenue growth expectations were offset by high cancellation rates and unclear management responses on key issues like AI impact and M&A environment. While product development and market strategy showed some positive signs, concerns over pass-through costs and the lack of specific guidance on cancellation trends and burn rate create uncertainties. The absence of a new partnership announcement or major shareholder return plan further tempers positive sentiment, resulting in a neutral outlook for the stock price over the next two weeks.